Muscle wasting is common among patients with end-stage renal disease (ESRD) who are receiving dialysis, and associates with increased morbidity and mortality.[@bib1], [@bib2], [@bib3] In the earlier stages of chronic kidney disease (CKD), the association of muscle mass with outcomes is less well defined. There are few data on mortality associated with sarcopenia, or low muscle mass, although it is common among individuals with advanced predialysis kidney disease.[@bib4] Studies that have examined urinary creatinine excretion and total lean body mass have yielded inconsistent results.[@bib5], [@bib6], [@bib7]

Accurate prognostication may require simultaneously examining the muscle and fat compartments. Body mass index (BMI) levels in the overweight and obese range are associated with the lowest mortality risk in CKD patients.[@bib8] However, persons with CKD who have excess adiposity but are also sarcopenic---a not uncommon finding---are very unlikely to be classified as obese by BMI.[@bib9], [@bib10] In hemodialysis patients, this phenotype, called sarcopenic obesity, is associated with greater inflammation and increased mortality.[@bib11] The prognostic significance of sarcopenic obesity in persons with CKD is not known.[@bib12]

We hypothesized that sarcopenia and sarcopenic-obesity are associated with increased all-cause mortality among individuals with CKD who are not on dialysis. Our definition of CKD was restricted to persons with estimated glomerular filtration rate (eGFR) of \<60 ml/min/1.73 m^2^ because the pathophysiologic link between CKD and low muscle mass is greatest in this subgroup, and our prior work demonstrated that the prevalence of sarcopenia increased below this threshold.[@bib10] We tested this hypothesis using nationally representative data from the National Health and Nutrition Examination Survey (NHANES), including dual-energy x-ray absorptiometry (DEXA)−derived muscle and fat mass to classify participants into 4 mutually exclusive body composition categories: nonsarcopenic nonobese, obese, sarcopenic, and sarcopenic-obese.[@bib10] Our objective was to examine this question among persons with CKD and to determine whether associations differed from those in individuals without CKD in the same nationally representative dataset. We hypothesized that associations of both sarcopenia and sarcopenic obesity with death would be stronger in persons with CKD than in those without, as CKD-induced muscle wasting is likely a poor prognostic factor.

When we initially conducted our analyses, linked mortality data were available with follow-up through December 31, 2006. Subsequently, we repeated our analyses when updated data became available with mortality status ascertained through December 31, 2011. We considered our findings from analyses conducted using the 2011 dataset to be our primary results, given the greater statistical power and longer follow-up time. However, we also compared the results obtained using each of these datasets to examine the impact of the duration of follow-up time on our findings.

Materials and Methods {#sec1}
=====================

Study Population {#sec1.1}
----------------

NHANES 1999--2004 was a program of studies designed to assess the health and nutritional status of noninstitutionalized civilians in the United States.[@bib13] The NHANES protocol was approved by the National Center for Health Statistics ethics review board, and written informed consent was obtained from all participants. We examined adults ≥20 years old (n = 15,332) with available body composition data (n = 12,732), excluding participants with eGFR \<15 ml/min/1.73 m^2^ (n = 34) or missing data on covariates of interest (n = 1082). The resultant cohort had 11,616 participants.

Data Collection {#sec1.2}
---------------

Information on race/ethnicity, education, smoking status, and comorbidities was based on self-report. Activity level was calculated as metabolic equivalents (MET-min/wk) based on questions regarding the frequency and duration of activities such as walking, cycling, home or yard work, and moderate or vigorous leisure activity performed within the past 30 days.[@bib14] Participants with diabetes mellitus were defined as those who had a physician diagnosis while not pregnant, were using insulin or oral hypoglycemic medications, or had a glycohemoglobin level of ≥6.5%. Hypertension was defined by systolic blood pressure of ≥140 mm Hg, diastolic blood pressure of ≥90 mm Hg, history of physician diagnosis, and/or antihypertensive medication use.[@bib15] Cardiovascular disease was defined by self-report of a physician diagnosis of congestive heart failure, coronary heart disease, angina, myocardial infarction, or stroke.

Serum chemistries were measured using the Hitachi 917 multichannel analyzer (Roche Diagnostics, Indianapolis, IN) in 1999 to 2001 and the Beckman Synchron LX20 (Beckman Coulter Inc., Brea, CA) in 2002 to 2004. C-reactive protein (CRP) was quantified by latex-enhanced nephelometry. Serum albumin was measured by the bromocresol purple method. A modified kinetic Jaffe reaction was used to measure serum creatinine, and the values from 1999 to 2000 were calibrated to the Cleveland Clinic laboratory standard by multiplying by 1.013 and adding 0.147. Values from 2001 to 2004 did not need correction. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.[@bib16] CKD was defined as an eGFR of \<60 ml/min/1.73 m^2^.

### Body Composition Data {#sec1.2.1}

Missing and invalid DEXA data were accounted for through multiple imputation by the National Center for Health Statistics.[@bib17] Details of the DEXA quality control, data validation, and multiple imputation procedures are available elsewhere.[@bib17], [@bib18], [@bib19], [@bib20] DEXA data for at least 1 body region were imputed in 2472 participants (21.3%). Muscle mass was quantified using the appendicular skeletal muscle mass index (ASMI; total lean mass of the 4 extremities divided by the square of the height).[@bib21] Sarcopenia was defined as ASMI of \<5.45 kg/m^2^ in women and \<7.26 kg/m^2^ in men.[@bib21], [@bib22] These cutoffs correspond to 2 SDs below the sex-specific means for healthy young adults 18 to 40 years of age and are recommended by the consensus guidelines of the European Working Group on Sarcopenia in Older People.[@bib23], [@bib24] We examined ASMI rather total lean mass based on this recommendation, and also because appendicular lean mass is not confounded by changes in visceral lean mass due to chronic disease and is likely more relevant for functional status. Obesity was determined as percentage of total body fat (TBF) greater than 42.1% for women and 29.6% for men, corresponding to the sex-specific 60th percentile for the study sample[@bib22] and to the current World Health Organization guidelines for BMI-defined obesity.[@bib25], [@bib26]

Outcome Variables {#sec1.3}
-----------------

All-cause mortality was determined primarily through probabilistic record matching with the National Death Index and was available using public-use linked mortality files.[@bib27], [@bib28] Mortality status was initially ascertained through December 31, 2006,[@bib29] and then additional data became available with mortality status ascertained through December 31, 2011.[@bib30] The date and cause of death for selected records were subjected to data perturbation techniques because of concerns regarding participant anonymity, but vital status was not perturbed. The results of Cox proportional hazard models are not affected by these data perturbation techniques when compared with nonperturbed restricted-use data.[@bib31], [@bib32]

Statistical Analysis {#sec1.4}
--------------------

Participant characteristics were examined within body composition categories, for the overall cohort and for those with eGFR of \<60 ml/min/1.73 m^2^. Differences across categories were tested for statistical significance using linear regression, logistic regression, or multinomial regression as appropriate. Kaplan−Meier survivor functions were examined within body composition categories for the overall cohort and for those with eGFR of \<60 ml/min/1.73 m^2^ and tested for statistical significance using the Cox test of equality and accounting for NHANES sampling weights. Cox proportional hazards models were created to examine associations of body composition categories with all-cause mortality. We examined unadjusted models, followed by adjustment for age, sex, and race/ethnicity, and then multivariable models that included potential confounders of the association of body composition with mortality, including education level, physical activity, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer excluding nonmelanoma skin cancer, eGFR, and urine albumin−creatinine ratio. We then created separate models additionally adjusting for serum albumin and CRP, which, as markers of inflammation, may lie in the causal pathway with body composition and mortality. The functional form of continuous variables was tested for linearity using higher-order terms and categorical variables. We tested for interaction by CKD status by including multiplicative interaction terms in the models, and then repeated our analyses separately among participants with eGFR of \<60 ml/min/1.73 m^2^ and ≥60 ml/min/1.73 m^2^. Effect modification by other covariates was tested using multiplicative interaction terms. The proportional hazards assumption was tested by visual inspection of log−log plots. All analyses used NHANES-appropriate sampling weights and all except the Kaplan−Meier analyses accounted for the complex multistage cluster design using the "survey" command in Stata 13.1 (Stata Corporation, College Station, TX). A *P* value of \<0.05 was considered statistically significant.

### Sensitivity Analyses {#sec1.4.1}

We performed a matched-pair analysis in which we repeated our analyses in a cohort in which each participant with an eGFR of \<60 ml/min/1.73 m^2^ was uniquely matched with a participant with eGFR of ≥60 ml/min/1.73 m^2^ based on age (±1 year), sex, and non-Hispanic black status. To determine whether our findings were explained by early mortality related to sarcopenia, we repeated our analyses after excluding participants who died within 24 months of their NHANES examination. We explored confounding related to the use of creatinine-based eGFR by repeating our analyses using cystatin C−based eGFR[@bib33] in the subgroup with cystatin C measurements. To determine whether similar findings were observed without using threshold definitions for body composition components, we examined associations with all-cause mortality when ASMI and percentage of total body fat (%TBF) were modeled as continuous variables.

Results {#sec2}
=======

Participant Characteristics {#sec2.1}
---------------------------

Overall, 10.9% of participants were sarcopenic but not obese, and 3.4% were sarcopenic-obese. Compared with the other body composition categories, sarcopenic-obese participants were older, more likely to be male, and to be non-Hispanic white, current or former smokers, less active, and to have hypertension, cardiovascular disease, eGFR of \<60 ml/min/1.73 m^2^, and urine albumin−creatinine ratio of \>30 mg/g ([Table 1](#tbl1){ref-type="table"}). They also had a higher prevalence of diabetes, lower serum albumin, and higher CRP than nonsarcopenic nonobese and sarcopenic nonobese participants but not compared with obese participants. The mean BMI was similar between sarcopenic-obese and nonsarcopenic nonobese participants, whereas for the former group, %TBF was similar to that in obese participants, and ASMI was similar to that in sarcopenic non-obese participants.Table 1Participant characteristics by body composition category in 11,616 participants of NHANES 1999--2004CharacteristicNonsarcopenic, nonobeseSarcopenia onlyObese onlySarcopenic-obese*P***Proportion (%)**49.4 (0.9)10.9 (0.4)36.2 (0.7)3.4 (0.2)**Age (yr)**42.2 (0.3)47.9 (0.6)49.5 (0.3)63.4 (0.9)\<0.001**Women (%)**50.3 (0.6)52.6 (1.6)51.6 (0.7)42.3 (2.7)0.009**Race/ethnicity (%)**\<0.001 **Non-Hispanic white**69.9 (1.6)76.5 (2.3)73.7 (1.8)81.7 (3.3) **Mexican American**7.2 (0.7)7.0 (1.0)7.5 (1.2)4.9 (1.3) **Non-Hispanic black**12.1 (1.1)3.7 (0.5)10.2 (1.1)1.9 (0.5) **Other**10.8 (1.3)12.8 (1.8)8.6 (1.3)11.5 (2.7)**BMI (kg/m**^2)^25.8 (0.1)20.9 (0.1)33.7 (0.2)25.2 (0.1)\<0.001**BMI ≥ 30 kg/m**^2^**, proportion (%)**10.8 (0.5)069.8 (1.2)2.3 (0.6)\<0.001**Education (% ≥ high school)**81.2 (0.8)78.5 (1.5)78.9 (0.8)76.1 (3.0)0.02**Smoking status**\<0.001 **Never**51.143.350.840.9 **Former**21.622.430.036.5 **Current**27.434.219.222.5**Activity level (MET-min/wk, %)**\<0.001 **0**13.1 (0.7)19.7 (1.3)19.6 (0.9)25.0 (2.8) **\<500**17.9 (1.3)20.7 (1.5)24.3 (0.8)27.2 (2.4) **500--2000**35.1 (0.7)36.0 (1.5)35.2 (0.8)30.4 (3.0) **\>2000**33.8 (0.9)23.6 (1.6)20.9 (1.1)17.5 (2.3)**Hypertension (%)**30.1 (1.0)32.0 (2.0)54.0 (1.1)66.7 (3.4)\<0.001**Diabetes mellitus (%)**5.5 (0.5)4.5 (0.6)14.2 (0.6)10.9 (1.7)\<0.001**Cardiovascular disease (%)**5.2 (0.5)9.0 (0.8)11.4 (0.6)22.0 (2.7)\<0.001**History of cancer (%)**4.7 (0.4)8.8 (0.7)7.4 (0.5)17.5 (2.0)\<0.001**eGFR \<60 ml/min/1.73 m**^2^**(%)**4.1 (0.3)7.3 (0.8)8.1 (0.4)17.8 (1.9)\<0.001**UACR \>30 mg/g (%)**6.9 (0.4)11.2 (1.2)10.9 (0.7)17.0 (2.0)\<0.001**Serum bicarbonate (mEq/l)**24.2 (0.1)24.6 (0.1)23.9 (0.1)24.6 (0.2)0.001**Serum albumin (g/dl)**4.40 (0.01)4.40 (0.01)4.25 (0.01)4.31 (0.02)\<0.001**Serum CRP \>1 mg/dl (%)**5.1 (0.4)6.1 (0.7)16.2 (0.7)12.6 (1.8)\<0.001**% Total body fat**30.2 (0.1)29.1 (0.2)40.4 (0.1)38.4 (0.4)\<0.001**ASMI (kg/m**^2^**)**7.6 (0.0)5.6 (0.0)8.4 (0.0)6.0 (0.1)\<0.001[^1]

Of 11,616 participants, 1101 had an eGFR of \<60 ml/min/1.73 m^2^ ([Table 2](#tbl2){ref-type="table"}). Sarcopenia without obesity and sarcopenic obesity were present in 12.5% and 9.7%, respectively. Differences in demographic characteristics across categories were similar to those in the full cohort, but there was less variation in the prevalence of comorbidities. Patterns of variation across categories for BMI, activity level, serum albumin, CRP, %TBF, and ASMI were similar to those in the full cohort. Compared with participants with eGFR of ≥60 ml/min/1.73 m^2^, those with eGFR of \<60 ml/min/1.73 m^2^ had an increased risk of death (hazard ratio \[HR\] = 1.59, 95% confidence interval \[CI\] = 1.36--1.85 after age, sex, and race/ethnicity adjustment; HR = 1.25, 95% CI = 1.06--1.48 after multivariable adjustment). There was a nonlinear association of eGFR with mortality ([Table S1](#appsec1){ref-type="sec"}).Table 2Participant characteristics by body composition category in 1101 participants of NHANES 1999--2004 with eGFR of \<60 ml/min/1.73 m^2^CharacteristicNonsarcopenic, nonobeseSarcopenia onlyObese onlySarcopenic obese*P***Proportion (%)**31.6 (1.8)12.5 (1.2)46.2 (2.1)9.7 (1.1)**Age (yr)**70.6 (1.0)75.2 (1.1)70.8 (0.8)77.2 (1.0)\<0.001**Women (%)**69.0 (3.3)53.3 (5.1)61.3 (2.3)35.5 (5.0)\<0.001**Race/ethnicity (%)**\<0.001 **Non-Hispanic white**79.5 (2.3)88.5 (3.0)82.4 (2.5)90.3 (3.4) **Mexican American**1.6 (0.5)1.6 (0.6)1.5 (0.4)2.0 (1.0) **Non-Hispanic black**11.7 (1.7)2.1 (1.0)8.6 (1.2)0.6 (0.7) **Other**7.2 (2.2)7.9 (2.7)7.5 (2.3)7.2 (3.0)**BMI (kg/m**^2^**)**26.2 (0.2)21.7 (0.2)32.8 (0.4)25.5 (0.3)\<0.001**BMI ≥ 30 kg/m**^2^**proportion (%)**10.6 (2.3)064.8 (2.2)2.6 (2.0)\<0.001**Education (% ≥ high school)**66.9 (3.1)64.4 (6.0)67.3 (2.5)68.6 (5.7)0.96**Smoking status**0.004 **Never**61.040.151.345.2 **Former**31.341.341.747.6 **Current**7.718.67.07.2**Activity level (MET-min/wk, %)**0.03 **0**25.1 (2.6)39.1 (5.0)34.4 (2.3)33.9 (5.7) **\<500**20.7 (2.6)20.1 (4.3)24.3 (2.6)27.9 (5.7) **500--2000**33.8 (3.5)25.6 (4.2)26.8 (2.4)29.5 (5.6) **\>2000**20.4 (2.5)15.2 (4.4)14.5 (1.8)8.7 (2.8)**Hypertension (%)**83.3 (2.7)86.7 (4.1)91.4 (1.4)89.5 (3.8)0.03**Diabetes mellitus (%)**20.8 (3.0)17.5 (4.0)26.6 (2.5)18.1 (4.5)0.19**Cardiovascular disease (%)**30.9 (3.2)35.8 (4.3)37.7 (2.7)42.8 (5.7)0.26**History of cancer (%)**17.8 (2.7)19.9 (4.0)17.7 (2.0)30.9 (5.4)0.11**UACR ≥30 mg/g (%)**26.1 (3.5)31.9 (3.9)28.5 (2.1)32.1 (4.8)0.63**Serum bicarbonate (mEq/l)**24.4 (0.2)24.7 (0.3)24.3 (0.2)23.8 (0.4)0.21**Serum albumin (g/dl)**4.27 (0.02)4.15 (0.03)4.14 (0.02)4.17 (0.04)\<0.001**Serum CRP ≥1 mg/dl (%)**7.5 (1.9)10.6 (3.1)17.3 (1.7)12.6 (4.1)0.007**% Total body fat**34.2 (0.4)31.3 (0.6)41.7 (0.4)37.6 (0.6)\<0.001**ASMI (kg/m**^2^**)**7.1 (0.1)5.7 (0.1)7.8 (0.1)6.1 (0.1)\<0.001[^2]

Associations of Sarcopenia Status With Mortality {#sec2.2}
------------------------------------------------

The median follow-up time for mortality status through 2006 and 2011 was 56 months (interquartile range \[IQR\] = 39--73) (707 deaths) and 113 months (IQR = 94--130) (1695 deaths), respectively. When classifying body composition as either sarcopenic or nonsarcopenic, sarcopenic participants had an increased risk of mortality ([Table 3](#tbl3){ref-type="table"}, top panel) after multivariable adjustment and after additional adjustment for CRP and serum albumin. We found significant effect modification by CKD status (*P* \< 0.001 for interaction). After multivariable adjustment, sarcopenia was associated with an increased risk of mortality in participants with eGFR of ≥60 ml/min/1.73 m^2^ (HR = 1.34, 95% CI = 1.15--1.57) but not those with eGFR of \<60 ml/min/1.73 m^2^, although this nearly reached statistically significance (HR = 1.25, 95% CI = 1.00--1.57). Adjustment for CRP and serum albumin as markers of inflammation somewhat magnified this risk in participants with eGFR of ≥60 ml/min/1.73 m^2^ but not \<60 ml/min/1.73 m^2^. Analyses using the 2006 dataset yielded similar results ([Table 3](#tbl3){ref-type="table"}, bottom panel).Table 3Association of sarcopenia with all-cause mortality in 11,616 participants of NHANES 1999--2004[∗](#tbl3fnlowast){ref-type="table-fn"}Mortality status through 2011Body compositionHR (95% CI)Model 1Model 2Model 3Model 4Entire cohort (n = 11,616)NonsarcopenicReferenceReferenceReferenceReferenceSarcopenic**2.52 (2.24--2.83)1.43 (1.29--1.59)1.28 (1.15--1.43)1.32 (1.19--1.48)**Participants with eGFR ≥60 ml/min/1.73 m^2^ (n = 10,515)NonsarcopenicReferenceReferenceReferenceReferenceSarcopenic**2.48 (2.11--2.92)1.54 (1.34--1.78)1.34 (1.15--1.57)1.42 (1.21--1.66)**Participants with eGFR \<60 ml/min/1.73 m^2^ (n = 1101)NonsarcopenicReferenceReferenceReferenceReferenceSarcopenic**1.89 (1.54--2.32)1.33 (1.05--1.68)**1.25 (1.00--1.57)1.24 (0.98--1.58)Mortality status through 2006Body compositionHR (95% CI)Model 1Model 2Model 3Model 4Entire cohort (n = 11,616)NonsarcopenicReferenceReferenceReferenceReferenceSarcopenic**2.83 (2.37--3.38)1.51 (1.22--1.86)1.33 (1.06--1.67)1.38 (1.11--1.73)**Participants with eGFR ≥60 ml/min/1.73 m^2^ (n = 10,515)NonsarcopenicReferenceReferenceReferenceReferenceSarcopenic**2.89 (2.27--3.68)1.74 (1.35--2.25)1.47 (1.12--1.94)1.56 (1.19--2.04)**Participants with eGFR \<60 ml/min/1.73 m^2^ (n = 1101)NonsarcopenicReferenceReferenceReferenceReferenceSarcopenic**1.85 (1.36--2.52)**1.21 (0.83--1.78)1.17 (0.84--1.68)1.19 (0.84--1.68)[^3][^4]

Associations of Body Composition Categories With Mortality {#sec2.3}
----------------------------------------------------------

Sarcopenic-obese participants had the highest overall mortality ([Figure 1](#fig1){ref-type="fig"}a). After multivariable adjustment, sarcopenia without obesity and sarcopenic obesity were significantly associated with increased mortality compared with the nonsarcopenic nonobese phenotype ([Table 4](#tbl4){ref-type="table"}, top panel). There was significant effect modification of these associations by CKD status (*P* = 0.01). Among participants with eGFR of ≥60 ml/min/1.73 m^2^, both sarcopenia without obesity and sarcopenic obesity were associated with an increased risk of mortality after multivariable adjustment ([Table 4](#tbl4){ref-type="table"}, top panel). The associations of all covariates with mortality in the multivariable-adjusted model are presented in [Table S1](#appsec1){ref-type="sec"}. Further adjustment for CRP and serum albumin did not meaningfully change these findings.Figure 1Kaplan−Meier survival curves for all-cause mortality by body composition category in participants of the National Health and Nutrition Examination Survey (NHANES) 1999--2004. (a) Kaplan−Meier survival curves by body composition category in 11,616 participants. (b) Kaplan−Meier survival curves by body composition category in 1101 participants with eGFR of \<60 ml/min/1.73 m^2^. *P* values calculated using the Cox test of equality and accounting for NHANES sampling weights.Table 4Association of body composition categories with all-cause mortality in 11,616 participants of NHANES 1999--2004[∗](#tbl4fnlowast){ref-type="table-fn"}Mortality status through 2011Body compositionHR (95% CI)Model 1Model 2Model 3Model 4Entire cohort (n = 11,616)Nonsarcopenic nonobeseReferenceReferenceReferenceReferenceSarcopenic**2.72 (2.25--3.29)1.62 (1.33--1.99)1.35 (1.10--1.67)1.32 (1.06--1.66)**Obese**2.09 (1.74--2.50)1.27 (1.05--1.52)**1.09 (0.90--1.32)0.98 (0.81--1.18)Sarcopenic-obese**6.99 (5.65--8.65)1.69 (1.38--2.06)1.35 (1.09--1.66)1.28 (1.04--1.57)**Participants with eGFR ≥60 ml/min/1.73 m^2^ (n = 10,515)Nonsarcopenic nonobeseReferenceReferenceReferenceReferenceSarcopenic**2.80 (2.14--3.66)1.79 (1.37--2.35)1.44 (1.07--1.93)1.45 (1.07--1.97)**Obese**2.24 (1.78--2.81)1.41 (1.12--1.77)**1.21 (0.96--1.54)1.09 (0.87--1.37)Sarcopenic-obese**7.45 (5.65--9.82)2.09 (1.61--2.70)1.64 (1.26--2.13)1.57 (1.19--2.05)**Participants with eGFR \<60 ml/min/1.73 m^2^ (n = 1101)Nonsarcopenic nonobeseReferenceReferenceReferenceReferenceSarcopenic**1.79 (1.32--2.44)1.46 (1.06--2.02)**1.24 (0.89--1.71)1.14 (0.80--1.64)Obese0.93 (0.72--1.19)1.00 (0.77--1.30)0.87 (0.67--1.12)0.77 (0.59--1.01)Sarcopenic-obese**1.83 (1.34--2.48)**1.19 (0.88--1.62)1.05 (0.75--1.46)0.97 (0.70--1.35)Mortality status through 2006Body compositionHR (95% CI)Model 1Model 2Model 3Model 4Entire cohort (n = 11,616)Nonsarcopenic nonobeseReferenceReferenceReferenceReferenceSarcopenic**2.99 (2.34--3.83)1.68 (1.29--2.19)1.39 (1.03--1.87)**1.34 (1.00--1.83)Obese**1.93 (1.51--2.47)**1.18 (0.92--1.50)1.00 (0.77--1.28)0.86 (0.67--1.12)Sarcopenic-obese**7.14 (5.43--9.40)1.65 (1.18--2.30)**1.23 (0.83--1.84)1.17 (0.81--1.70)Participants with eGFR ≥60 ml/min/1.73 m^2^ (n = 10,515)Nonsarcopenic nonobeseReferenceReferenceReferenceReferenceSarcopenic**3.13 (2.20--4.48)1.95 (1.38--2.75)1.52 (1.02--2.26)**1.51 (1.00--2.30)Obese**2.11 (1.53--2.90)**1.34 (0.97--1.85)1.15 (0.83--1.60)1.00 (0.71--1.40)Sarcopenic-obese**8.26 (5.51--12.38)2.30 (1.42--3.72)1.75 (1.07--2.87)1.63 (1.02--2.61)**Participants with eGFR \<60 ml/min/1.73 m^2^ (n = 1101)Nonobese nonsarcopenicReferenceReferenceReferenceReferenceSarcopenic**1.79 (1.17--2.74)**1.38 (0.87--2.18)1.24 (0.80--1.90)1.16 (0.74--1.81)Obese0.87 (0.62--1.24)0.94 (0.68--1.29)0.77 (0.55--1.07)**0.67 (0.47--0.95)**Sarcopenic-obese**1.61 (1.03--2.50)**0.95 (0.57--1.58)0.77 (0.48--1.23)0.73 (0.46--1.17)[^5][^6]

Among participants with eGFR of \<60 ml/min/1.73 m^2^, sarcopenic nonobese and sarcopenic-obese participants had the highest overall mortality ([Figure 1](#fig1){ref-type="fig"}b). Compared with nonsarcopenic nonobese participants, no body composition category was associated with an increased risk of death after multivariable adjustment ([Table 4](#tbl4){ref-type="table"}, top panel). For obese and sarcopenic-obese individuals, these associations differed significantly from participants without CKD (*P* value for interaction by CKD status: sarcopenia without obesity, *P* = 0.22; obesity, *P* = 0.01; sarcopenic obesity, *P* = 0.003). Furthermore, after accounting for inflammation, there was a nonsignificant trend toward reduced risk of death among obese participants (HR = 0.77, 95% CI = 0.59--1.01). Findings were similar using the 2006 dataset, except that there was also a trend toward a reduced risk of death among sarcopenic-obese participants, similar to obese persons, in those with eGFR of \<60 ml/min/1.73 m^2^ ([Table 4](#tbl4){ref-type="table"}, bottom panel).

Because obesity was the most populous body composition category among participants with eGFR of \<60 ml/min/1.73 m^2^, and because prior studies have suggested that obese dialysis patients may have the greatest survival, we also examined associations with mortality compared to that in obese persons ([Figure 2](#fig2){ref-type="fig"}a). When obese participants were considered the reference group, sarcopenia without obesity was significantly associated with increased mortality (HR = 1.43, 95% CI = 1.05--1.95)). With shorter duration of follow-up in the 2006 dataset, the risk of death was magnified for nonsarcopenic nonobese participants and for sarcopenic nonobese participants, but not for sarcopenic-obese persons ([Figure 2](#fig2){ref-type="fig"}b). Additional adjustment for serum albumin and CRP increased the risk of death relative to obesity for each of the other body composition categories.Figure 2All-cause mortality compared to that in obese persons among National Health and Nutrition Examination Survey (NHANES) participants with an estimated glomerular filtration rate (eGFR) of \<60 ml/min/1.73 m^2^. CI, confidence interval; HR, hazard ratio. (a) Mortality ascertained through 2011. (b) Mortality ascertained through 2006. Multivariable-adjusted model adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, and log-transformed urine albumin−creatinine ratio. Inflammation-adjusted model additionally adjusted for serum albumin and log-transformed C-reactive protein. CI, confidence interval; HR, hazard ratio.

There was significant interaction between body composition and race/ethnicity (*P* interaction = 0.003 in the entire cohort); examination within the 2 eGFR subgroups suggested that the mortality risk of sarcopenia might be greater in non-Hispanic black participants compared to other race/ethnicity categories ([Table S2](#appsec1){ref-type="sec"}), but this effect did not appear to differ based on eGFR.

### Sensitivity Analyses {#sec2.3.1}

As the differences that we observed between the 2 eGFR subgroups could have been related to underlying differences in demographic characteristics, we repeated our analyses in a cohort in which each participant with an eGFR of \<60 ml/min/1.73 m^2^ was uniquely matched with a participant with eGFR of ≥60 ml/min/1.73 m^2^ based on age (±1 year), sex, and non-Hispanic black status. This resulted in 965 unique pairs (957/965 with age difference = 0 years). These results did not differ substantively from our main results, and there was a significant interaction by CKD status (*P* = 0.04) ([Table S3](#appsec1){ref-type="sec"}). After excluding participants who died in the first 2 years of follow-up, sarcopenia was significantly associated with mortality in participants with and without eGFR of \<60 ml/min/1.73 m^2^ ([Table S4](#appsec1){ref-type="sec"}). Compared with obese participants with eGFR of \<60 ml/min/1.73 m^2^, the mortality HRs for those who were sarcopenic nonobese or sarcopenic-obese increased in magnitude ([Table S5](#appsec1){ref-type="sec"}). Cystatin C data were available in 3949 participants, 755 of whom had an eGFR of \<60 ml/min/1.73 m^2^. Repeating our analyses using cystatin C eGFR in this smaller sample yielded qualitatively similar results ([Tables S6 and S7](#appsec1){ref-type="sec"}). Modeling ASMI and %TBF as continuous variables demonstrated an association of higher %TBF with lower risk of mortality only among participants with CKD ([Table S8](#appsec1){ref-type="sec"}). There was a similar nonsignificant association when restricted to sarcopenic individuals.

Discussion {#sec3}
==========

In a nationally representative cohort, we found that the risk of death in persons with CKD differs if muscle and fat mass are examined together rather than in isolation. BMI is of limited utility in this regard. Nearly 10% of participants with CKD and reduced eGFR were sarcopenic-obese, and their mean BMI was no different than that of individuals with normal body composition.

We hypothesized that associations of sarcopenia and sarcopenic obesity with increased mortality would be greater in persons with CKD than in those without. Our findings do not support this hypothesis. Although sarcopenia in the absence of obesity was an independent risk factor for increased mortality, this relationship was modified by eGFR. Among participants with CKD, the increased risk of death was present only when compared with that of obese persons but not those with normal body composition. Also contrary to our hypothesis, sarcopenic obesity was not associated with higher mortality among persons with CKD, in contrast to those with eGFR of ≥60 ml/min/1.73 m^2^; rather, in our initial analyses of mortality status ascertained through 2006, the results suggested a reduced risk of death in these participants similar to that seen among obese individuals. Although this protective association seemed to be attenuated with greater duration of follow-up time (when mortality status was ascertained through 2011), the risk of death was still not significantly increased.

Whereas the association of body composition abnormalities with outcomes has been studied extensively in the ESRD population, it has been less well-examined in persons with predialysis CKD. Most studies have focused on obesity, using BMI as the defining metric.[@bib8], [@bib34], [@bib35] Muscle mass has been examined directly and indirectly in only a few studies, with conflicting results. One report of 287 CKD patients found increased mortality among those who were sarcopenic,[@bib4] whereas another using NHANES data found no association of total lean body mass with survival in persons with CKD.[@bib6] Conversely, 2 studies reported that lower urinary creatinine excretion was associated with an increased risk of death in CKD patients, suggesting that lower muscle mass is a poor prognostic factor.[@bib5], [@bib7] However, it is not clear that these associations were due to differences in muscle mass. In the Chronic Renal Insufficiency Cohort study, fat-free mass measured by bioelectrical impedance analysis was only moderately correlated with creatinine excretion and did not similarly associate with mortality.[@bib7] Factors other than muscle mass, such as dietary intake and the ability to complete a 24-hour urine collection, may have mediated differences in measured urinary creatinine excretion in these studies.

Appendicular skeletal muscle mass may be more appropriate to examine in relation to mortality, as it is more directly related to functional ability and is not confounded by differences in visceral lean mass. Our report used a threshold for low appendicular muscle mass that is recommended by the European consensus guidelines for defining sarcopenia.[@bib23] Although the current guidelines also recommend including functional measures in the definition, we focused on muscle mass because of the limited number of individuals with functional assessments in this NHANES cohort. Despite this limitation, our findings demonstrate that low muscle mass is predictive of mortality risk in the general population and in persons with CKD.

There are several possible explanations for the association of sarcopenia with mortality in persons with CKD. Kidney disease may cause muscle wasting via accelerated muscle protein breakdown, possibly mediated by inflammation or insulin resistance.[@bib36], [@bib37], [@bib38] This could affect survival through several mechanisms. Better preserved muscle mass could help maintain functional status, decreasing the risk of falls, fractures, and the negative effects of a sedentary lifestyle.[@bib23] Greater skeletal muscle mass could improve metabolism, enhance peripheral glucose disposal, and increase energy stores.[@bib39] Intriguingly, inhibition of muscle proteolysis in a murine model of CKD not only preserved muscle mass but improved survival as well.[@bib40] If the quantity of functional skeletal muscle indeed mediates mortality risk in CKD, this could also explain some of the early survival benefit attributed to obesity. Even in the CKD subgroup, the individuals in the obese-only category had greater muscle mass than those with normal body composition.

Accelerated aging likely also contributes to the development of sarcopenia in persons with CKD. Adjustment for reduced activity level and comorbid conditions, markers of unsuccessful aging, attenuated the association with mortality but did not fully explain our findings. Similarly, inflammation has been linked with the development of sarcopenia[@bib41], [@bib42]; however, our results remained significant even after adjustment for serum albumin and CRP. Sarcopenia may be a marker of accelerated aging independent of these factors.[@bib43] On the other hand, although we attempted to account for differences in comorbidity and other characteristics among body composition categories, residual confounding may still explain some of our findings. In addition, sarcopenia could simply be a marker for sicker individuals with a greater burden of chronic illness. If this were the case, then our results could be due to an excess of early deaths among these sicker individuals. However, we did not see attenuation of risk with longer follow-up or when we excluded early mortality. It is possible that exclusion of death beyond the first 2 years might be required to detect such an effect. Regardless, we cannot exclude the possibility that differences in body composition are simply markers for other health-related characteristics.

Our findings illustrate the complexity of studying body composition in patients with CKD, even before the onset of ESRD. In the general population with eGFR of ≥60 ml/min/1.73 m^2^, sarcopenia was associated with mortality whether we classified participants based on sarcopenia status alone or simultaneously accounted for adiposity. When classifying participants with reduced eGFR based on sarcopenia status alone, it appeared there was a weaker association with mortality than in participants without CKD. A more detailed classification of body composition was required to clarify this association. In individuals with reduced eGFR, whether sarcopenia was associated with an increased risk of death depended on whether an individual was also obese by %TBF criteria. The favorable prognostic value of obesity seemed to outweigh the mortality risk of sarcopenia, although this effect diminished with longer follow-up time. Surprisingly, excluding early mortality in our sensitivity analyses magnified the risk of death in persons with CKD. This is in stark contrast to the general population cohort with eGFR of ≥60 ml/min/1.73 m^2^.

Most interventional studies in the general population have targeted either obesity or sarcopenia, but few have examined the sarcopenic-obese phenotype directly.[@bib44] Concerns have been raised about weight loss interventions in these individuals, because muscle mass is lost along with fat mass. It has been suggested that exercise should accompany supervised weight loss protocols in these circumstances.[@bib44] We are not aware of any interventional studies addressing this issue in CKD patients, and our data do not indicate whether interventions targeted at sarcopenic-obese CKD patients could be expected to improve survival. Although some would argue that weight loss may not be appropriate given the reduced risk of death with obesity and sarcopenic obesity in early follow-up, exercise including strength training seems a logical intervention to test. This could be expected to affect outcomes such as disability, falls, and quality of life, which may be adversely affected by both sarcopenia and obesity.[@bib45], [@bib46]

Several limitations of our study should be noted. The number of participants with eGFR of \<60 ml/min/1.73 m^2^ was relatively small, thus limiting the power to detect significant associations. For example, in the CKD cohort, the association of sarcopenia with mortality might have been statistically significant had a larger sample size been available for analysis. Similarly, when we further characterized body composition, the small sample of sarcopenic-obese individuals with CKD limited our ability to detect statistically significant associations. Nevertheless, there was significant effect modification by CKD status even within the smaller matched-pairs cohort, and the direction and magnitude of the point estimates were similar to our main results. Also, the definition of obesity did not account for the distribution of adipose tissue, and others have used different cutpoints for defining obesity based on adiposity. However, sarcopenic obesity defined using this %TBF cutoff has been associated with disability in community-dwelling elderly,[@bib22] and our previous work found that American Society of Bariatric Physicians cutpoints (30% for women and 25% for men) would provide limited discriminatory power because they would classify \>90% of individuals with CKD stage 3 and 4 as obese.[@bib10] Future studies should examine the interaction of abdominal obesity with sarcopenia in the CKD population. DEXA may overestimate lean mass in persons with edema; this could have attenuated our risk estimates, as participants with CKD would be most likely to have edema and to have an overestimation of lean mass. As only cross-sectional laboratory data were available, we could not define CKD based on the presence of an eGFR of \<60 ml/min/1.73 m^2^ for at least 3 months. Finally, given the observational nature of this study, we have determined associations but cannot comment on causality.

In conclusion, sarcopenia is associated with increased mortality in the CKD population, but the presence of obesity modifies this relationship. Unlike in the general population, obesity seems to blunt the mortality risk of sarcopenia in persons with CKD. Future studies should assign supervised weight loss and different types of exercise interventions after accounting for the complex alterations in body composition that occur in CKD patients but are not detected by BMI.
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[^1]: Data are expressed as mean SE or as percentage (SE). ASMI, appendicular skeletal muscle mass index; BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; MET, metabolic equivalent; NHANES, National Health and Nutrition Examination Survey; UACR, urine albumin−creatinine ratio.

[^2]: Data are expressed as mean SE or percentage (SE). ASMI, appendicular skeletal muscle mass index; CKD, chronic kidney disease; CRP, C-reactive protein; MET, metabolic equivalent; NHANES, National Health and Nutrition Examination Survey; UACR, urine albumin−creatinine ratio.

[^3]: Model 1: unadjusted. Model 2: adjusted for age, sex, race/ethnicity. Model 3: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, and log-transformed urine albumin-creatinine ratio. Model 4: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, log-transformed urine albumin−creatinine ratio, serum albumin, log-transformed C-reactive protein. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NHANES, National Health and Nutrition Examination Survey.

[^4]: *P* value for interaction by CKD status: mortality status through 2011, *P* \< 0.001; mortality status through 2006, *P* = 0.002. Boldface values indicate *P* \< 0.05.

[^5]: Model 1: unadjusted. Model 2: adjusted for age, sex, race/ethnicity. Model 3: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, and log-transformed urine albumin-creatinine ratio. Model 4: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, log-transformed urine albumin−creatinine ratio, serum albumin, log-transformed C-reactive protein. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NHANES, National Health and Nutrition Examination Survey.

[^6]: *P* value for interaction by CKD status: mortality through 2011, *P* = 0.01; mortality status through 2006, *P* = 0.01. Boldface values indicate *P* \< 0.05.
